NeuroBionics Raises $10M in Oversubscribed Seed Funding to Advance Minimally Invasive Neurotechnology

NeuroBionics, a Cambridge, Massachusetts–based neurotechnology startup spun out of the Massachusetts Institute of Technology, has been making waves in the medtech world with its latest funding achievements as it pushes toward first-in-human studies of its minimally invasive neuromodulation platform. The company, which is developing hair-thin bioelectronic fibers designed to deliver neuromodulation therapy endovascularly, closed an oversubscribed seed financing that has drawn backing from a diverse group of venture investors and strategic backers.

Founded in 2023 by CEO Dr. MJ Antonini alongside co-founders Dr. Nicki Driscoll and Prof. Polina Anikeeva, NeuroBionics aims to transform how deep brain stimulation and related neuromodulation therapies are delivered by eliminating the need for invasive craniotomy procedures. Its technology, rooted in over a decade of research at MIT, uses carbon-based fibers thin enough to be deployed through the vascular system to stimulate and record neural activity.

In January 2025, the company announced the successful close of a $5 million seed round, securing capital to accelerate device development, expand its clinical and engineering teams, and support preclinical safety and efficacy studies. This initial tranche was led by Dolby Family Ventures, a venture firm known for backing deep-tech and health-tech innovators. It also featured participation from Future Ventures, GreyMatter Capital, Focalpoint Partners, Lionheart Ventures, Jumpspace Ventures, and Thomas Insel, the former director of the U.S. National Institute of Mental Health.

That seed financing was described as oversubscribed, reflecting strong interest from both traditional venture capital firms and individuals with deep expertise in neuroscience and technology investments. Company leadership said the funds would be instrumental in advancing the first clinical product toward preclinical milestones and expanding its world-class team of engineers and neuroscientists.

Building on that initial success, NeuroBionics closed a second close of its seed round in late 2025, with Future Ventures taking the lead on new capital commitments. This follow-on brought in additional participation from investors including Vanedge Capital, Gaingels, and Opus 44, along with continued support from Lionheart Ventures.

Taken together, these tranches brought total seed funding to approximately $10 million, underscoring growing investor confidence in NeuroBionics’ approach and milestones achieved to date. The follow-on round was aimed at strengthening the company’s position as it progresses toward first-in-human feasibility studies and prepares essential regulatory filings.

The company’s funding story emerged against a backdrop of increased interest in neurotechnology solutions that reduce the invasiveness of brain therapies. Traditional deep brain stimulation procedures, which involve drilling into the skull to implant electrodes, present significant barriers for many patients. NeuroBionics’ strategy—using endovascular deployment of flexible fibers that can modulate and record neural signals from within blood vessels—promises a potentially safer, more accessible path to treat conditions ranging from Parkinson’s disease and epilepsy to mood disorders and chronic pain.

Early interest in the company’s technology extended beyond venture capital rounds. In 2024, NeuroBionics was named a Vision Award winner at the Wilson Sonsini Medical Device Digital Health Conference, earning non-dilutive prize funding and industry recognition.

As of early 2026, NeuroBionics stands as one of the more prominent neurotech startups emerging from MIT’s research ecosystem, with a funding foundation designed to carry it through critical regulatory and clinical inflection points. Its expanding investor base, which blends traditional venture firms and individual strategic backers, reflects a broader trend of capital flowing into technologies that promise to broaden access to advanced neurological therapies.